TY - BOOK
T1 - Combination and integration to redirect NK cells for cancer immunotherapy
AU - Gong, Ying
PY - 2021
Y1 - 2021
N2 - Cancer is a disease with still a high mortality. The number of new cases is still increasing globally despite current treatments. Therefore, new therapies with high specificity and efficiency to control the progress of cancer are urgently needed in the clinic. Nowadays, new cancer treatments emerged that are based on the immune system that have achieved encouraging outcomes. Together these modalities are called tumour immunotherapy. In this current PhD thesis, we have continued our group’s previous research on developing novel approaches for cancer immunotherapies are based on natural killer (NK) cells. This research demonstrated multiple methods to enhance the anti-tumour capacities of NK cells: 1) a combination with an anti-tumour antibody, 2) introduced an activation chimeric antigen receptor (CAR), 3) CRISPR/Cas9 genetic deletion of an inhibitory signal. These NK cell combinatorial approaches are ready for scale-up to be implemented into clinical treatments to the ultimate benefit of patients.
AB - Cancer is a disease with still a high mortality. The number of new cases is still increasing globally despite current treatments. Therefore, new therapies with high specificity and efficiency to control the progress of cancer are urgently needed in the clinic. Nowadays, new cancer treatments emerged that are based on the immune system that have achieved encouraging outcomes. Together these modalities are called tumour immunotherapy. In this current PhD thesis, we have continued our group’s previous research on developing novel approaches for cancer immunotherapies are based on natural killer (NK) cells. This research demonstrated multiple methods to enhance the anti-tumour capacities of NK cells: 1) a combination with an anti-tumour antibody, 2) introduced an activation chimeric antigen receptor (CAR), 3) CRISPR/Cas9 genetic deletion of an inhibitory signal. These NK cell combinatorial approaches are ready for scale-up to be implemented into clinical treatments to the ultimate benefit of patients.
KW - cancer immunotherapy
KW - natural killer cells
KW - genetic modification
KW - anti-tumour antibody
U2 - 10.26481/dis.20211130yg
DO - 10.26481/dis.20211130yg
M3 - Doctoral Thesis
SN - 9789464168303
PB - Maastricht University
CY - Maastricht
ER -